The group has over 20 years of experience in clinical and translational research on Alzheimer’s disease. The main scientific interest is the use of neuroimaging techniques and other biomarkers in persons with or at risk for cognitive impairment. Acquisitions and innovations in fundamental neurosciences, ICT, and technology are uptaken and translated for use into a clinical setting for better pathophysiological understanding, diagnosis, prognosis, disease tracking, drug therapy, and rehabilitation. Specific topics of investigation are: the clinical use of imaging and fluid biomarkers; in vivo neurobiology of Alzheimer’s disease; the clinical use of innovative PET ligands; harmonisation of imaging markers for clinical use; development of innovative image analysis environments based on advanced ICT technology.
Learning from the Past: a Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease.
Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
Low-Dose Radiation Therapy: A New Treatment Strategy for Alzheimer's Disease?
CSF cutoffs for MCI due to AD depend on APOEε4 carrier status.
Département de psychiatrie